Inosine pro-drug: novel therapy for arthritis

肌苷前药:关节炎的新疗法

基本信息

项目摘要

DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is mediated by articular expression of pro-inflammatory cytokines and chemokines. We have discovered that the purine degradation product inosine exerts multiple anti-inflammatory and immunomodulatory effects via combined A2a and A3 agonism, resulting in suppressed expression of TNF-alpha, IL-1 beta, IL-12, MIP-lalpha, and IFN-gamma and enhanced expression of IL-10. We have recently developed a proprietary pro-drug of inosine, 5'-inosine monosulfate (IMS),that is more potent than inosine in vivo and shows dramatic protection against inflammatory injury. In a collagen-induced murine model of autoimmune arthritis, IMS profoundly reduced the incidence and severity of arthritis, reduced TNF-alpha and MIP-lalpha expression, and virtually eliminated neutrophil infiltration and lipid peroxidation. Coupled with the fact that free inosine is an approved OTC nutritional supplement and has an excellent record of safety in man, we envision the introduction of its prodrug IMS as a novel pharmaceutical for the treatment of RA. The Specific Aims of this Fast-Track proposal are: Phase I: Establish that IMS reverses established experimental arthritis and is effective in combination with current clinical anti-arthritic therapies. IMS will be provided to DBA/1J mice rendered arthritic by repeated injection of collagen. Our preliminary data show that introduction of IMS prior to the onset of disease is nearly fully protective. In order to establish the reversibility of established disease, IMS therapy will be introduced at day 35, after the onset of joint disease in this model system. We will also determine whether a one-week pulse of IMS therapy, initiated at day 20, will provide persistent protection against the development of arthritis in the DBA/1J model. Finally, we will establish the synergy of IMS, begun on day 20, with traditional anti-arthritic therapies, including ibuprofen and methotrexate. Progression to Phase II SBIR will require that IMS produces a 50% reduction in the severity of established collagen-induced arthritis and that IMS is synergistic with ibuprofen or methotrexate. In the Phase 2 SBIR, we will determine the pre-clinical pharmacokinetics and biochemical, hematologic, and histopathologic toxicology, and safety pharmacology profile of IMS. The proposed studies will provide the foundation for Phase la and lb clinical safety trials of IMS.
描述(由申请人提供):风湿性关节炎(RA)由促炎细胞因子和趋化因子的关节表达介导。我们已经发现嘌呤降解产物肌苷通过组合的A2 α和A3激动作用发挥多种抗炎和免疫调节作用,导致TNF-α、IL-1 β、IL-12、MIP-1 α和IFN-γ的表达受到抑制,而IL-10的表达得到增强。我们最近开发了一种专有的肌苷前药,5 '-肌苷单硫酸盐(IMS),它在体内比肌苷更有效,并显示出对炎症损伤的显著保护作用。在胶原蛋白诱导的自身免疫性关节炎小鼠模型中,IMS显著降低关节炎的发病率和严重程度,降低TNF-α和MIP-1 α表达,并几乎消除中性粒细胞浸润和脂质过氧化。再加上游离肌苷是一种被批准的OTC营养补充剂,并且在人体中具有良好的安全性记录,我们设想将其前药IMS作为一种新型药物用于治疗RA。这个快速通道提案的具体目标是:第一阶段:确定IMS逆转已建立的实验性关节炎,并与目前的临床抗关节炎疗法联合使用有效。将IMS提供给DBA/1 J小鼠,通过重复注射胶原蛋白使其患关节炎。我们的初步数据表明,在疾病发作前引入IMS几乎是完全保护性的。为了确定已建立疾病的可逆性,将在该模型系统中关节疾病发作后的第35天引入IMS治疗。我们还将确定在第20天开始的为期一周的IMS脉冲治疗是否会在DBA/1 J模型中提供持久的保护作用,以防止关节炎的发展。最后,我们将建立IMS的协同作用,从第20天开始,与传统的抗关节炎疗法,包括布洛芬和甲氨蝶呤。进展到II期SBIR将需要IMS使已建立的胶原诱导性关节炎的严重程度降低50%,并且IMS与布洛芬或甲氨蝶呤具有协同作用。在II期SBIR中,我们将确定IMS的临床前药代动力学和生化、血液学和组织病理学毒理学以及安全药理学特征。拟定的研究将为IMS的Ia期和Ib期临床安全性试验提供基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW Lurie SALZMAN其他文献

ANDREW Lurie SALZMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW Lurie SALZMAN', 18)}}的其他基金

Treatment of congenital heart disease associated pulmonary hypertension
先天性心脏病相关肺动脉高压的治疗
  • 批准号:
    8831801
  • 财政年份:
    2015
  • 资助金额:
    $ 139.67万
  • 项目类别:
A Novel Immunotolerizing Therapy for Autoimmune Vitiligo
一种治疗自身免疫性白癜风的新型免疫耐受疗法
  • 批准号:
    8713488
  • 财政年份:
    2014
  • 资助金额:
    $ 139.67万
  • 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
  • 批准号:
    9342949
  • 财政年份:
    2012
  • 资助金额:
    $ 139.67万
  • 项目类别:
Resuscitation of smoke inhalation and burn injury with a thioredoxin mimetic
用硫氧还蛋白模拟物复苏烟雾吸入和烧伤
  • 批准号:
    8338756
  • 财政年份:
    2012
  • 资助金额:
    $ 139.67万
  • 项目类别:
A Redox-active PARP Inhibitor for Lung Transplantation
用于肺移植的氧化还原活性 PARP 抑制剂
  • 批准号:
    8391286
  • 财政年份:
    2012
  • 资助金额:
    $ 139.67万
  • 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
  • 批准号:
    9140177
  • 财政年份:
    2012
  • 资助金额:
    $ 139.67万
  • 项目类别:
Bifunctional Redox Catalyst & Organic Nitrate for Limb Reperfusion
双功能氧化还原催化剂
  • 批准号:
    8522327
  • 财政年份:
    2011
  • 资助金额:
    $ 139.67万
  • 项目类别:
PARP inhibition for thoraco-abdominal aneurysm surgery
PARP 抑制在胸腹动脉瘤手术中的应用
  • 批准号:
    6933563
  • 财政年份:
    2005
  • 资助金额:
    $ 139.67万
  • 项目类别:
PARP inhibitory therapy of acute ischemic stroke
PARP抑制治疗急性缺血性脑卒中
  • 批准号:
    6785744
  • 财政年份:
    2004
  • 资助金额:
    $ 139.67万
  • 项目类别:
PARP inhibitor therapy for septic shock
PARP 抑制剂治疗感染性休克
  • 批准号:
    6790412
  • 财政年份:
    2004
  • 资助金额:
    $ 139.67万
  • 项目类别:

相似海外基金

Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10630757
  • 财政年份:
    2022
  • 资助金额:
    $ 139.67万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10598619
  • 财政年份:
    2022
  • 资助金额:
    $ 139.67万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10434316
  • 财政年份:
    2022
  • 资助金额:
    $ 139.67万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10831324
  • 财政年份:
    2022
  • 资助金额:
    $ 139.67万
  • 项目类别:
Employing the gut microbiome to accelerate effective initiation of rheumatoid arthritis therapy
利用肠道微生物组加速类风湿关节炎治疗的有效启动
  • 批准号:
    10240299
  • 财政年份:
    2019
  • 资助金额:
    $ 139.67万
  • 项目类别:
Engineering smart cells for arthritis therapy
工程智能细胞用于关节炎治疗
  • 批准号:
    9912537
  • 财政年份:
    2019
  • 资助金额:
    $ 139.67万
  • 项目类别:
Employing the gut microbiome to accelerate effective initiation of rheumatoid arthritis therapy
利用肠道微生物组加速类风湿关节炎治疗的有效启动
  • 批准号:
    10686275
  • 财政年份:
    2019
  • 资助金额:
    $ 139.67万
  • 项目类别:
Employing the gut microbiome to accelerate effective initiation of rheumatoid arthritis therapy
利用肠道微生物组加速类风湿关节炎治疗的有效启动
  • 批准号:
    10470803
  • 财政年份:
    2019
  • 资助金额:
    $ 139.67万
  • 项目类别:
Utilizing eQTL Databases to Identify New Potential Targets in Rheumatoid Arthritis Therapy
利用 eQTL 数据库识别类风湿关节炎治疗的新潜在靶点
  • 批准号:
    18K16140
  • 财政年份:
    2018
  • 资助金额:
    $ 139.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy
开发用于类风湿性关节炎治疗的小分子 TLR5 抑制剂
  • 批准号:
    9408815
  • 财政年份:
    2017
  • 资助金额:
    $ 139.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了